Career Opportunities in Biotechnology and Drug Development (Hardcover)

Career Opportunities in Biotechnology and Drug Development (Hardcover)by Toby Friedman (Author).

As the world of biotechnology has grown in leaps and bounds, so too have the career opportunities. But the choices can be daunting. What types of jobs are available? How do you get your foot in the door? What will your job entail if you become a "Preclinical Project Manager" or a "Process Scientist"? What s the difference between biotech and pharma?

Career Opportunities in Biotechnology and Drug Development provides a comprehensive and systematic overview of careers in the life science industry, with all their ups and downs. The author, Toby Freedman, Ph.D., has conducted interviews with hundreds of key players in the industry, who provide first hand explanations of their day to day roles and responsibilities, and offer key insights into how they landed those jobs in the first place. Careers in everything from discovery research to venture capital are covered in detail.

Each chapter includes valuable sections on preparing yourself for a prospective career: educational requirements and personality characteristics needed; recommendations of books, magazines, and Web site resources; and issues to consider regarding salary and compensation. The book also includes interviewing and job searching tips, as well as suggestions on writing a resume specifically for industry.

Career Opportunities in Biotechnology and Drug Development is an essential guide for science graduates and medical, business, legal, high tech or engineering professionals. With discussions of job security, future trends, and potential career paths, even those already working in industry will find helpful information on how to take advantage of opportunities available within their own companies and elsewhere. This book will help you make wiser and more informed decisions about what role you would like to play in the biotechnology and drug development industry.

The Nanotech Future: A Conversation with Mihail Roco

Nanotechnology refers to the emerging science of manufacturing materials that are measured in nanometers, usually at the 1-100 nanometers scale. The head of a pin is 1 million nanometers wide. By 2014, Lux Research estimates that $2.6 trillion in manufactured goods will incorporate nanotechnology, or about 15 percent of global output.

What was Dr. Rocos vision in 2000 at the start of the NNI? What are his expectations for nanotechnologys many promises-in medicine, sustainable energy, and electronics? What challenges does nanotechnology pose for the future, particularly as it reaches toward third and fourth generation development-in guided molecular assembly, 3D networking, robotics, supra-molecules, molecules by design, and evolutionary systems?

Robert Service, nanotechnology reporter at Science magazine, will interview Dr. Roco about nanotechnology at a Friday, November 9th, 2007, 12:30 p.m. event and live webcast at the Woodrow Wilson International Center for Scholars.

The event is sponsored by the Project on Emerging Nanotechnologies ( http://www.nanotechproject.org ), a joint initiative of the Wilson Center and The Pew Charitable Trusts. Project director David Rejeski will introduce the program.

Prior to joining the National Science Foundation, Dr. Roco was Professor of Mechanical Engineering at the University of Kentucky ((1981-1995), and held visiting professorships at the California Institute of Technology (1988-89), Johns Hopkins University (1993-1995), Tohoku University (1989) and Delft University of Technology (1997-1998). He is credited with 13 inventions, and has authored and co-authored numerous articles, publications and books.

Dr. Roco will receive the National Materials Advancement Award from the Federation of Materials Societies at the National Press Club in Washington, DC on December 5, 2007.

He is Corresponding Member of the Swiss Academy of Sciences, Fellow of the American Institute of Chemical Engineering, Fellow of the Institute of Physics and Fellow of the American Society of Mechanical Engineering. Dr. Roco initiated work on converging technologies, and on societal implications of nanotechnology since the beginning of the NNI.

FDA Clears Genetic Lab Test for Warfarin Sensitivity

The U.S. Food and Drug Administration today cleared for marketing a new genetic test that will help physicians assess whether a patient may be especially sensitive to the blood-thinning drug warfarin (Coumadin), which is used to prevent potentially fatal clots in blood vessels.

One-third of patients receiving warfarin metabolize it quite differently than expected and experience a higher risk of bleeding. Research has shown that some of the unexpected response to warfarin depends on variants of two genes, CYP2C9 and VKORC1. The Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test detects some variants of both genes.

"Today’s action offers physicians the first FDA cleared genetic test for warfarin sensitivity, which is another step in our commitment to personalized medicine,” said Daniel Schultz, M.D., director, FDA’s Center for Devices and Radiological Health. “With this test, physicians may be able to use genetic information along with other clinical information to treat their patients.”

Warfarin can be a difficult drug to use because the optimal dose varies depending on many risk factors, including a patient's diet, age, and the use of other medications. Rapidly achieving the correct dose is important. Patients who receive doses that are higher than needed to correctly thin the blood are at risk of life-threatening bleeding. Those who receive doses that are too low may remain at risk of life-threatening blood clots.

Warfarin is the second most common drug, after insulin, implicated in emergency room visits for adverse drug events.

In August, FDA approved updated labeling for Coumadin, the brand name version of warfarin, explaining that people with variations of the genes CYP2C9 and VKORC1 may respond differently to the drug. Manufacturers of generic warfarin are adding similar information to their products' labeling.

Physicians and other health care professionals who prescribe warfarin regularly check to see if the drug is working properly by ordering a test called the PT or prothrombin time that evaluates the blood's ability to clot properly. The results are measured in seconds and compared with the expected value in healthy people, known as the International Normalized Ratio or INR.

The Nanosphere test is not intended to be a stand-alone tool to determine optimum drug dosage, but should be used along with clinical evaluation and other tools, including INR, to determine the best treatment for patients.

FDA cleared the test based on results of a study conducted by the manufacturer of hundreds of DNA samples as well as on a broad range of published literature. In a three site study, the test was accurate in all cases where the test yielded a result; 8 percent of the tests could not identify which genetic variants were present.

The new test was cleared for use on the Verigene System, a clinical laboratory test system. Both products are manufactured by Nanosphere Inc., Northbrook, Ill.